Clinical sequencing identifies potential actionable alterations in a high rate of urachal and primary bladder adenocarcinomas.

ABSTRACT:

Objective

Administration of targeted therapies provides a promising treatment strategy for urachal adenocarcinoma (UrC) or primary bladder adenocarcinoma (PBAC); however, the selection of appropriate drugs remains difficult. Here, we aimed to establish a routine compatible methodological pipeline for the identification of the most important therapeutic targets and potentially effective drugs for UrC and PBAC.

Methods

Next-generation sequencing, using a 161 cancer driver gene panel, was performed on 41 UrC and 13 PBAC samples. Clinically relevant alterations were filtered, and therapeutic interpretation was performed by in silico evaluation of drug-gene interactions.

Results

After data processing, 45/54 samples passed the quality control. Sequencing analysis revealed 1

SUBMITTER: Varadi M 

PROVIDER: S-EPMC10134276 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature